Loading...
•
Dec 31, 2021
Puma Biotechnology Q4 2021 Earnings Report
Puma Biotechnology reported an increase in revenue and a shift from net loss to net income in Q4 2021.
Key Takeaways
Puma Biotechnology reported financial results for the fourth quarter and year ended December 31, 2021. The company's total revenue for Q4 2021 was $55.4 million, with a net income of $4.2 million, or $0.10 per basic and diluted share. Non-GAAP adjusted net income was $8.4 million, or $0.21 per basic and diluted share.
Total revenue for the fourth quarter of 2021 was $55.4 million.
Net income for the fourth quarter of 2021 was $4.2 million, or $0.10 per basic and diluted share.
Non-GAAP adjusted net income for the fourth quarter of 2021 was $8.4 million, or $0.21 per basic and diluted share.
Puma anticipates key milestones over the next 12 months, including FDA meetings and reporting Phase II data from clinical trials.
Revenue by Segment
Forward Guidance
Puma Biotechnology anticipates several key milestones over the next 12 months, including meetings with the FDA and reporting Phase II data from clinical trials.
Positive Outlook
- Conducting a pre-NDA meeting with the FDA to discuss accelerated approval of neratinib in HER2-mutated HR-positive breast cancer (H1 2022).
- Reporting Phase II data from the cohort of patients in the SUMMIT basket trial of neratinib in HER2-mutated HR-positive breast cancer (H1 2022).
- Reporting Phase II data from the cohort of patients in the SUMMIT basket trial of neratinib in non-small cell lung cancer patients with EGFR exon 18 mutations (H2 2022).
- Conducting a meeting with the FDA to discuss the potential for an accelerated approval pathway for neratinib in non-small cell lung cancer patients with EGFR exon 18 mutations who have previously been treated with an EGFR tyrosine kinase inhibitor (2022).
- Reporting Phase II TBCRC-022 trial data from Cohort 4B and 4C of the combination of Kadcyla® plus neratinib in patients with HER2-positive breast cancer with brain metastases who have previously been treated with Kadcyla (H2 2022).
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...